Tag Archives: value-based pricing

Tough Times Ahead for New Medicines under NHS England?

By Guest Blogger | Published: April 22, 2013
By Leela Barham You’d be forgiven for missing it with the vast array of new agencies and the policy documents, guidance, consultations and ‘engagement’ activity they’re doing on in the ‘new’ NHS in England, but on the 4th April NHS England (formerly the NHS Commissioning Board) set out 15 commissioning policies in 250 pages.  They’re important, [...]
Posted in Europe, Global, Guest Blog, healthcare, pricing | Also tagged , , , , | Leave a comment

England's Cancer Drug Fund: An Acid Test for Value Based Pricing

By Guest Blogger | Published: April 12, 2013
By Leela Barham. England’s Cancer Drugs Fund (CDF) could be in its final financial year, after running in full since April 2011.  The fund covers the cost of cancer treatments either when NICE has said ‘no’, or hasn’t yet come to a view.  Companies can’t circumvent NICE though; if a company was invited to submit to [...]
Posted in Europe, Global, Guest Blog, Op-Ed, pricing | Also tagged , , , , | Leave a comment

Value-Based Pricing Could Counter Innovation, Says UK Think Tank

By Julian Upton | Published: March 25, 2011
The UK government’s proposals to introduce value-based pricing (VBP) — which aims to create a stronger link between the price the National Health Service pays for a medicine and the value it delivers (and in the process, ostensibly, further incentivize therapeutic innovation) — could actually serve to ‘hinder’ innovation, according to a UK think tank.
Posted in Europe, Global, R&D, pricing | Also tagged , , , , , | Leave a comment

Wins and Losses from Risk-Sharing Agreements

By William Looney | Published: November 17, 2010
Can you manage the external market impact? Risk-sharing agreements – where companies contract with reimbursement or assessment authorities to guarantee a new drug’s performance, often against specific outcomes measures, in return for access to patients – are among the latest innovations in managing health care costs. Use of the tool is standard in Australia, is [...]
Posted in Europe, Global, Regulatory, Strategy, healthcare, pricing | Also tagged , , , , , | Leave a comment

NICE News or Bad News?

By William Looney | Published: November 3, 2010
Far from losing its mojo, the UK’s National Institute for Health and Clinical Excellence (NICE) will simply be sharing the stage with a range of new players under NHS reform — none of whom look supportive of the R&D industry. The big issue for industry in the UK this week is handicapping the future of its [...]
Posted in Europe, Global, Regulatory | Also tagged , , , , , , , | Leave a comment